HIV-1 Escape from Small-Molecule Antagonism of Vif

MBio
Mark SharkeyMario Stevenson

Abstract

The HIV-1 accessory protein Vif, which counteracts the antiviral action of the DNA-editing cytidine deaminase APOBEC3G (A3G), is an attractive and yet unexploited therapeutic target. Vif reduces the virion incorporation of A3G by targeting the restriction factor for proteasomal degradation in the virus-producing cell. Compounds that inhibit Vif-mediated degradation of A3G in cells targeted by HIV-1 would represent a novel antiviral therapeutic. We previously described small molecules with activity consistent with Vif antagonism. In this study, we derived inhibitor escape HIV-1 variants to characterize the mechanism by which these novel agents inhibit virus replication. Here we show that resistance to these agents is dependent on an amino acid substitution in Vif (V142I) and on a point mutation that likely upregulates transcription by modifying the lymphocyte enhancing factor 1 (LEF-1) binding site. Molecular modeling demonstrated a docking site in the Vif-Elongin C complex that is disrupted by these inhibitors. This docking site is lost when Vif acquires the V142I mutation that leads to inhibitor resistance. Competitive fitness experiments indicated that the V142I Vif and LEF-1 binding site mutations created a virus that is bet...Continue Reading

References

Jan 1, 1994·Annual Review of Biochemistry·K A Jones, B M Peterlin
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·A Tutter, K A Jones
Dec 10, 1998·Nature Medicine·J H SimonM H Malim
Jun 18, 2003·Cell·Reuben S HarrisMichael H Malim
Mar 19, 2004·Journal of Medicinal Chemistry·Richard A FriesnerPeter S Shenkin
Mar 19, 2004·Journal of Medicinal Chemistry·Thomas A HalgrenJay L Banks
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Oct 19, 2007·Nucleic Acids Research·Yasumasa IwataniJudith G Levin
Jun 11, 2008·Cell Host & Microbe·Michael H Malim, Michael Emerman
Sep 23, 2008·Nature Biotechnology·Robin NathansTariq M Rana
Nov 29, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Michael H Malim
Dec 6, 2008·PLoS Pathogens·Kate N BishopMichael H Malim
Jan 20, 2009·Current HIV/AIDS Reports·Thomas GrambergNathaniel R Landau
May 20, 2015·Nature Structural & Molecular Biology·Takahide KounoHiroshi Matsuo
Aug 3, 2016·Nature Communications·Xiao XiaoXiaojiang S Chen
Aug 11, 2016·Journal of Medicinal Chemistry·Idrees MohammedTariq M Rana

❮ Previous
Next ❯

Datasets Mentioned

BETA
K02013
MH843935

Methods Mentioned

BETA
PCR

Software Mentioned

Ligprep
ClustalW
Schrödinger
Prime
Coot
MacVector
Sequencher

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.